Published in Blood on March 01, 1994
The kynurenine system and immunoregulation. J Neural Transm (Vienna) (2011) 1.38
Nitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2,3-dioxygenase. Infect Immun (2004) 1.16
Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7. J Exp Med (1995) 1.14
The concept of depression as a dysfunction of the immune system. Curr Immunol Rev (2010) 1.06
Potentiation of interferon-mediated inhibition of Chlamydia infection by interleukin-1 in human macrophage cultures. Infect Immun (1995) 1.01
Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol (2014) 0.93
How flaviviruses activate and suppress the interferon response. Viruses (2010) 0.92
IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia (2007) 0.90
Expression of the Kynurenine Pathway in Human Peripheral Blood Mononuclear Cells: Implications for Inflammatory and Neurodegenerative Disease. PLoS One (2015) 0.90
A new mechanism for inhalational priming: IL-4 bypasses innate immune signals. J Immunol (2008) 0.89
A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells. Immunity (2017) 0.85
The role of the kynurenine metabolism in major depression. J Neural Transm (Vienna) (2011) 0.85
Changes in the immune system in depression and dementia: causal or coincidental effects? Dialogues Clin Neurosci (2006) 0.84
Quantification of indoleamine 2,3-dioxygenase gene induction in atopic and non-atopic monocytes after ligation of the high-affinity receptor for IgE, Fc(epsilon)RI and interferon-gamma stimulation. Clin Exp Immunol (2003) 0.77
The role of placental indoleamine 2,3-dioxygenase in human pregnancy. Obstet Gynecol Sci (2013) 0.76
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med (1984) 4.73
The fine specificity of antigen and Ia determinant recognition by T cell hybridoma clones specific for pigeon cytochrome c. Cell (1982) 3.38
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med (1995) 2.88
Prolonged air leak following radical upper lobectomy: an analysis of incidence and possible risk factors. Chest (1998) 2.82
Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem (1998) 2.80
Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem (1996) 2.78
Bulgeless dwarf galaxies and dark matter cores from supernova-driven outflows. Nature (2010) 2.71
Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus. Nature (1986) 2.64
Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J Immunol (1996) 2.62
Death in the AIDS patient: role of cytomegalovirus. N Engl J Med (1983) 2.61
Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest (1995) 2.29
Absence of the Lyt-2-,L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function. J Exp Med (1985) 2.27
Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med (1985) 2.18
Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun (1997) 2.14
Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function. J Exp Med (1985) 2.14
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest (1998) 2.06
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther (1997) 1.86
Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem (1995) 1.80
Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under the control of different Ir genes and characterization of representative T cell clones. J Immunol (1984) 1.75
Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A (1999) 1.72
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood (2001) 1.71
Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol (1998) 1.70
Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol (1996) 1.70
Peripheral clonal elimination of functional T cells. Science (1990) 1.69
p53 mutation is associated with progression in follicular lymphomas. Blood (1993) 1.69
Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ (1994) 1.68
Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood (1992) 1.66
Murine syngeneic mixed lymphocyte response. I. Target antigens are self Ia molecules. J Exp Med (1981) 1.65
Fractures of the coracoid process. J Bone Joint Surg Br (1995) 1.63
Clonal analysis of the major histocompatibility complex restriction and the fine specificity of antigen recognition in the T cell proliferative response to cytochrome C. J Immunol (1983) 1.63
The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones. J Immunol (1983) 1.61
Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest (1998) 1.61
Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. Nature (1984) 1.58
The control of chemotherapy-induced emesis. Ann Intern Med (1981) 1.55
Differential inhibition of IL-1 and TNF-alpha mRNA expression by agents which block second messenger pathways in murine macrophages. J Immunol (1988) 1.55
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55
Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst (1993) 1.54
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol (1991) 1.53
T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest (1996) 1.53
Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther (2004) 1.52
Kappa B site-dependent activation of the interleukin-2 receptor alpha-chain gene promoter by human c-Rel. Mol Cell Biol (1992) 1.52
Small noncleaved cell lymphoma associated with florid epithelioid granulomatous response. A clinicopathologic study of seven patients. Am J Surg Pathol (1993) 1.51
Gene complementation. Neither Ir-GLphi gene need be present in the proliferative T cell to generate an immune response to Poly(Glu55Lys36Phe9)n. J Exp Med (1980) 1.49
Determination of water soluble imidazo-1,4-benzodiazepines in blood by electron- capture gas--liquid chromatography and in urine by differential pulse polaragraphy. J Chromatogr (1978) 1.48
Growth hormone as an immunomodulating therapeutic agent. Immunol Today (2000) 1.48
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol (1993) 1.46
Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases. Am J Surg Pathol (1993) 1.45
Heterogeneity of hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus infection of bone marrow or fetal liver. J Natl Cancer Inst (1989) 1.44
Lymphocytic lymphoma of intermediate differentiation--mantle zone lymphoma: a distinct subtype of B-cell lymphoma. Hum Pathol (1987) 1.44
Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood (1994) 1.43
Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol (2000) 1.41
Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer (1990) 1.40
Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1. J Immunol (1989) 1.39
Bcl-2 and Bcl-X(L) block thapsigargin-induced nitric oxide generation, c-Jun NH(2)-terminal kinase activity, and apoptosis. Mol Cell Biol (1999) 1.39
Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J Natl Cancer Inst (1995) 1.39
You say tomato and I say tomahto: getting a handle on pronouncing apoptosis. J Natl Cancer Inst (1997) 1.39
What's the deal with follicular lymphomas? J Clin Oncol (1993) 1.39
A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma. Cancer Invest (1998) 1.39
Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. J Immunol (2000) 1.38
Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst (1995) 1.37
Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ (1992) 1.37
Cell cycle regulation of the human polo-like kinase (PLK) promoter. J Biol Chem (1997) 1.37
Senescence-related changes in gene expression in muscle: similarities and differences between mice and men. Physiol Genomics (2001) 1.35
Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res (1993) 1.34
The 37-amino-acid interdomain of dengue virus NS5 protein contains a functional NLS and inhibitory CK2 site. Biochem Biophys Res Commun (1999) 1.33
Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J Biol Chem (1997) 1.33
Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res (1995) 1.33
The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res (1987) 1.32
Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J Immunol (1991) 1.31
Macrophage-colony-stimulating factor (CSF-1) induces proliferation, chemotaxis, and reversible monocytic differentiation in myeloid progenitor cells transfected with the human c-fms/CSF-1 receptor cDNA. Proc Natl Acad Sci U S A (1990) 1.31
Diagnostic peritoneal lavage analysis: should trauma guidelines be revised? Emerg Med J (2002) 1.30
Human RANTES induces the migration of human T lymphocytes into the peripheral tissues of mice with severe combined immune deficiency. Eur J Immunol (1994) 1.29
Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst (1990) 1.27
MYC rearrangements in histologically progressed follicular lymphomas. Blood (1992) 1.26
Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med (1984) 1.26
Viagra is licensed in Europe, but rationed in Britain. BMJ (1998) 1.25
Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med (1988) 1.25
A murine macrophage cell line, immortalized by v-raf and v-myc oncogenes, exhibits normal macrophage functions. Eur J Immunol (1987) 1.25
Genetic resistance/susceptibility to mycobacteria: phenotypic expression in bone marrow derived macrophage lines. J Leukoc Biol (1991) 1.24
Mapping quantitative trait loci affecting life history traits in the nematode Caenorhabditis elegans. Genetics (1996) 1.24
Faecal contamination of drinking water sources of Dhaka city during the 2004 flood in Bangladesh and use of disinfectants for water treatment. J Appl Microbiol (2007) 1.24
Treatment of peripheral neuroepithelioma in children and young adults. J Clin Oncol (1987) 1.24
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med (1983) 1.23
Junctional biases in the naive TCR repertoire control the CTL response to an immunodominant determinant of HSV-1. Immunity (2000) 1.22
Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst (1997) 1.22
Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res (1992) 1.21
Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reactions. Eur J Immunol (1992) 1.20
Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J Natl Cancer Inst (1992) 1.20
Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations. Blood (1988) 1.20
Expression and role of p75 interleukin 2 receptor on human monocytes. J Exp Med (1990) 1.19